Gail P. Risbridger

16.3k total citations · 1 hit paper
272 papers, 9.7k citations indexed

About

Gail P. Risbridger is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Gail P. Risbridger has authored 272 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 113 papers in Molecular Biology, 92 papers in Pulmonary and Respiratory Medicine and 54 papers in Reproductive Medicine. Recurrent topics in Gail P. Risbridger's work include Prostate Cancer Treatment and Research (85 papers), Sperm and Testicular Function (51 papers) and TGF-β signaling in diseases (50 papers). Gail P. Risbridger is often cited by papers focused on Prostate Cancer Treatment and Research (85 papers), Sperm and Testicular Function (51 papers) and TGF-β signaling in diseases (50 papers). Gail P. Risbridger collaborates with scholars based in Australia, United States and United Kingdom. Gail P. Risbridger's co-authors include Stuart J. Ellem, Renea A. Taylor, Stephen J. McPherson, Gerald R. Cunha, D.M. de Kretser, Mitchell G. Lawrence, Mark Frydenberg, David Robertson, Jacqueline F. Schmitt and J. B. Kerr and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Gail P. Risbridger

270 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling

2016 832 citations Mitchell G. Lawrence, Gail P. Risbridger et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gail P. Risbridger Australia	53	4.4k	2.9k	2.2k	1.6k	1.6k	272	9.7k
Jan‐Erik Damber Sweden	49	2.3k 0.5×	4.1k 1.4×	1.0k 0.5×	1.7k 1.0×	1.4k 0.9×	261	8.6k
Shuyuan Yeh United States	68	7.0k 1.6×	5.1k 1.7×	3.7k 1.7×	2.1k 1.3×	2.7k 1.7×	204	14.5k
Michael Koutsilieris Greece	51	3.2k 0.7×	1.5k 0.5×	987 0.5×	2.0k 1.2×	1.3k 0.8×	338	9.7k
Äkïhïko Okuyama Japan	50	3.3k 0.7×	1.7k 0.6×	1.4k 0.6×	860 0.5×	1.0k 0.6×	479	9.4k
Donald J. Tindall United States	70	8.4k 1.9×	7.0k 2.4×	3.0k 1.4×	2.4k 1.5×	3.3k 2.1×	206	16.1k
Albert O. Brinkmann Netherlands	56	5.3k 1.2×	4.0k 1.4×	4.7k 2.1×	807 0.5×	5.0k 3.1×	153	11.6k
Frank Claessens Belgium	53	4.5k 1.0×	2.6k 0.9×	3.4k 1.6×	1.0k 0.6×	2.7k 1.7×	205	9.5k
Elizabeth M. Wilson United States	62	7.3k 1.6×	3.7k 1.3×	5.0k 2.3×	854 0.5×	4.8k 3.0×	150	12.8k
Atsushi Mizokami Japan	49	3.4k 0.8×	3.4k 1.2×	1.1k 0.5×	2.4k 1.5×	1.4k 0.9×	386	8.8k
Michael J. McPhaul United States	51	3.8k 0.9×	1.3k 0.5×	2.8k 1.3×	518 0.3×	2.6k 1.6×	160	7.5k

Countries citing papers authored by Gail P. Risbridger

Since Specialization

Citations

This map shows the geographic impact of Gail P. Risbridger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gail P. Risbridger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gail P. Risbridger more than expected).

Fields of papers citing papers by Gail P. Risbridger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gail P. Risbridger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gail P. Risbridger. The network helps show where Gail P. Risbridger may publish in the future.

Co-authorship network of co-authors of Gail P. Risbridger

This figure shows the co-authorship network connecting the top 25 collaborators of Gail P. Risbridger. A scholar is included among the top collaborators of Gail P. Risbridger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gail P. Risbridger. Gail P. Risbridger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Du, Xin, Pei Kee Goh, Chenkai Ma, et al.. (2025). Targeting PTPN2 enhances human CAR T cell efficacy and the development of long-term memory in mouse xenograft models. Science Translational Medicine. 17(822). eadk0627–eadk0627.

Obinata, Daisuke, Ken‐ichi Takayama, Mitchell G. Lawrence, et al.. (2024). Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor. BMC Cancer. 24(1). 554–554. 4 indexed citations

Wang, Zifeng, Scott L. Townley, Mu‐Qing Li, et al.. (2024). FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer. Nature Communications. 15(1). 4914–4914. 13 indexed citations

Thomas, Patrick B., Gail P. Risbridger, Renea A. Taylor, et al.. (2022). Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. Cancers. 14(3). 503–503. 32 indexed citations

Lawrence, Mitchell G., Laura H. Porter, David Pook, et al.. (2021). CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics. 20(11). 2140–2150. 17 indexed citations

Clarke, Iain J., et al.. (2017). Mysterious inhibitory cell regulator investigated and found likely to be secretogranin II related. PeerJ. 5. e3833–e3833. 5 indexed citations

Rebello, Richard J., Eric Kusnadi, Donald P. Cameron, et al.. (2016). The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. Clinical Cancer Research. 22(22). 5539–5552. 61 indexed citations

Rebello, Richard J., Eric Kusnadi, Donald P. Cameron, et al.. (2016). The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer. European Journal of Cancer. 61. S167–S167. 10 indexed citations

Taylor, Renea A., Roxanne Toivanen, Mark Frydenberg, et al.. (2012). Human Epithelial Basal Cells Are Cells of Origin of Prostate Cancer, Independent of CD133 Status. Stem Cells. 30(8). 1786–1786. 4 indexed citations

10.

Centenera, Margaret M., Joanna L. Gillis, Adrienne R. Hanson, et al.. (2012). Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors. Clinical Cancer Research. 18(13). 3562–3570. 87 indexed citations

11.

Bajpai, Anurag, Peter Simm, Stephen J. McPherson, et al.. (2010). Peripubertal aromatase inhibition in male rats has adverse long-term effects on bone strength and growth and induces prostatic hyperplasia. Journal of Endocrinology. 207(1). 27–34. 14 indexed citations

12.

Cowin, Prue A., Elspeth Gold, Jasna Aleksova, et al.. (2010). Vinclozolin Exposure in Utero Induces Postpubertal Prostatitis and Reduces Sperm Production via a Reversible Hormone-Regulated Mechanism. Endocrinology. 151(2). 783–792. 41 indexed citations

13.

Ilić, Dragan, Gail P. Risbridger, & Sally Green. (2005). The informed man: Attitudes and information needs on prostate cancer screening. The Journal of Men s Health and Gender. 2(4). 414–420. 17 indexed citations

14.

Risbridger, Gail P.. (2003). Androgens vs estrogens in prostate cancer. 5. 1 indexed citations

15.

Risbridger, Gail P., et al.. (2001). The Metaplastic Effects of Estrogen on Mouse Prostate Epithelium: Proliferation of Cells with Basal Cell Phenotype¹. Endocrinology. 142(6). 2443–2450. 86 indexed citations

16.

Risbridger, Gail P.. (2001). The Metaplastic Effects of Estrogen on Mouse Prostate Epithelium: Proliferation of Cells with Basal Cell Phenotype. Endocrinology. 142(6). 2443–2450. 19 indexed citations

17.

Mellor, Sally L., Mark Cranfield, John Pedersen, et al.. (2000). Localization of Activin β_A-,β_B-, andβ_C-Subunits in Human Prostate and Evidence for Formation of New Activin Heterodimers ofβ_C-Subunit¹. The Journal of Clinical Endocrinology & Metabolism. 85(12). 4851–4858. 92 indexed citations

18.

McPherson, Stephen J., Sally L. Mellor, Hong Wang, et al.. (1999). Expression of Activin A and Follistatin Core Proteins by Human Prostate Tumor Cell Lines. Endocrinology. 140(11). 5303–5309. 49 indexed citations

19.

McFarlane, James R., et al.. (1994). Stimulatory and inhibitory factors of Leydig cell steroidogenesis are secreted simultaneously by the rat seminiferous tubules and do not affect Leydig cell inhibin production in vitro. Reproduction Fertility and Development. 6(6). 693–698. 3 indexed citations

20.

Risbridger, Gail P., et al.. (1981). Temporal changes in rat Leydig cell function after the induction of bilateral cryptorchidism. Reproduction. 63(2). 415–423. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact